These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 21034375

  • 1. Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
    Sicras-Mainar A, Navarro-Artieda R, Blanca-Tamayo M, Gimeno-de la Fuente V, Salvatella-Pasant J.
    Curr Med Res Opin; 2010 Dec; 26(12):2757-64. PubMed ID: 21034375
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K, Hemels ME, Hudry J, Annemans L.
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G, Danchenko N, Despiegel N, Marteau F.
    Value Health; 2012 Mar; 15(2):231-9. PubMed ID: 22433753
    [Abstract] [Full Text] [Related]

  • 7. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG, Toumi I, Hemels ME.
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [Abstract] [Full Text] [Related]

  • 8. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG, Toumi I, Hemels ME.
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [Abstract] [Full Text] [Related]

  • 9. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2003 Apr; 21(16):1185-209. PubMed ID: 14594439
    [Abstract] [Full Text] [Related]

  • 10. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC, Wisniewski SR, Balasubramani GK, Zisook S, Kurian B, Warden D, Trivedi MH, Rush AJ, CO-MED Study Team.
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [Abstract] [Full Text] [Related]

  • 11. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications.
    Vanoli A, Lane C, Harrison C, Steen N, Young A.
    J Psychopharmacol; 2008 Jun; 22(4):434-40. PubMed ID: 18635723
    [Abstract] [Full Text] [Related]

  • 12. [Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting].
    Sicras-Mainar A, Blanca-Tamayo M, Gutiérrez-Nicuesa L, Salvatella-Pasant J, Navarro-Artieda R.
    Gac Sanit; 2010 Jun; 24(1):13-9. PubMed ID: 19646795
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
    Fernandez JL, Montgomery S, Francois C.
    Pharmacoeconomics; 2005 Jun; 23(2):155-67. PubMed ID: 15748090
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G, Despiegel N, Marteau F, Danchenko N, Maman K.
    J Med Econ; 2010 Jun; 13(3):516-26. PubMed ID: 20698748
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 16. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Wang J, Liu X, Mullins CD.
    Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
    [Abstract] [Full Text] [Related]

  • 17. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 18. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
    Montgomery SA, Huusom AK, Bothmer J.
    Neuropsychobiology; 2004 Feb; 50(1):57-64. PubMed ID: 15179022
    [Abstract] [Full Text] [Related]

  • 19. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [Abstract] [Full Text] [Related]

  • 20. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
    Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.
    Manag Care; 2012 Jan; 21(1):49-58. PubMed ID: 22332457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.